feature1

ISTO Technologies CFO: No Other Company Can Grow Living Cartilage in a Lab Setting

April 30, 2013 OneMedPlace Team 0

ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product — a bone graft extender and substitute — and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.

DelMar IPO Obscurity Could Offer Investors Favorable Entry

April 26, 2013 OneMedPlace Contributor 0

DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).

No Image

White Paper Explores the Amarantus Bioscience Alzheimer’s Disease Diagnostic

April 25, 2013 OneMedPlace Team 0

Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.

Idrasil: The First Medical Marijuana Pill, and Parallels in Opiate Market

April 24, 2013 OneMedPlace Team 0

California-based C3 International has brought to market the first medical marijuana pill, known as Idrasil. OneMedRadio spoke with C3 International Chairman Steele Clarke Smith III about the unique delivery technology behind Idrasil, and trends in the sector related to market opportunity, necessity for non-inhaled delivery and dialogue in the medical community.

The Beginning of a Shift at Tekmira: From Focus on Delivery to Therapy

April 23, 2013 Jake King 0

Tekmira’s (TKMR) story over the last few years has largely been focused on its siRNA delivery technology, lipid nanoparticles (LNPs), and the ability of the platform to be used in broader RNAi applications. But the focus of investors is shifting as Tekmira brings a new therapy into the clinic this year and moves out of early-stage clinical development and into proof-of-concept studies.

Caprion’s Proteomic Biomarkers — Diverse Clientele Leads to In-House Pipeline

April 16, 2013 OneMedPlace Team 0

Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.

Healthcare Providers an Interesting Investment Field, Not Only For Private Equity

April 15, 2013 OneMedPlace Team 0

The landscape of healthcare is changing and whoever is smart will watch closely. With the introduction of Obamacare in 2013, the US stands to see a substantial increase in the number of insured individuals. And because the correlation between time and age has always been positive, Uncle Sam will be attending to millions of North Americans turning 65 yearly, their growing healthcare bill in tow.